---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: OP-1250-001"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: OP-1250-001. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 68 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence/op-1250-001"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: OP-1250-001

<a id="heading-3.1.2"></a>

## 3.1.2 OP-1250-001

<a id="heading-3.1.2.1"></a>

### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

#### Study objectives

> “This study (NCT04505826) was an open-label, multicenter, phase 1/2 study designed to identify the maximum tolerated dose (MTD), establish the recommended phase 2 dose (RP2D), and investigate the safety, pharmacokinetics (PK), and antitumor activity of single-agent palazestrant in patients with previously treated ER+/HER2− advanced and metastatic breast cancer”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.1-2"></a>

#### Primary and secondary objectives

> “Primary objectives: Pharmacokinetics, safety, tolerability, RP2D”
> “Secondary objectives: ORR, CBR (CR + PR + SD ≥24 weeks)”
> “Objectives: Efficacy, safety and tolerability at RP2D”

Source: [Lin et al. (2023)](https://ir.olema.com/static-files/d0053fca-ac05-4adc-abb4-9c6ba4ec0ae6)

<a id="heading-3.1.2.2"></a>

### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

#### Study sites and enrollment period

> “The analysis presented here includes clinical and laboratory data from 146 patients recruited at 15 sites in the US and Australia between August 2020 and November 2022.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.2-2"></a>

#### Trial registration and data cutoff of the primary publication

> “ClinicalTrials.gov, NCT04505826. Registered August 6, 2020.”
> “at the time of data cutoff (July 7, 2023)”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.2-3"></a>

#### Last participant enrolled

> “Last patient enrolled Nov 2022”

Source: [Lin et al. (2023)](https://ir.olema.com/static-files/d0053fca-ac05-4adc-abb4-9c6ba4ec0ae6)

<a id="topic-3.1.2.2-4"></a>

#### Interim data cutoff: dose escalation

> “Data cut-off date for this analysis was October 1, 2021”
> “A total of 40 patients were treated between August 2020 and October 2021”

Source: [Patel et al. (2021)](https://olema.com/wp-content/uploads/2023/08/Olema_Final-SABCS-Poster_11.29.21.pdf)

<a id="topic-3.1.2.2-5"></a>

#### Interim data cutoff: dose escalation and dose expansion

> “Data cut-off date for this analysis was 2 September 2022”

Source: [Hamilton et al. (2022)](https://olema.com/wp-content/uploads/2022/10/Olema_ENA-2022_NCT04505826_FINAL-10.26.22.pdf)

<a id="heading-3.1.2.3"></a>

### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

#### Dose escalation and dose expansion phases

> “Phase 1 of the study comprised a dose-escalation phase (1a) to identify the MTD using a rolling 6 patient dose-escalation design with 7 dose levels. Two doses of palazestrant (60 mg/day and 120 mg/day) were selected for the dose-expansion phase (1b) to further characterize the safety, PK, and preliminary antitumor activity of treatment and to establish the RP2D.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.3-2"></a>

#### Phase 2 cohorts at the recommended phase 2 dose

> “Phase 2 further explored the safety and antitumor activity of palazestrant at the RP2D (120 mg/day) in patients with measurable disease (primary cohort), nonmeasurable evaluable disease (exploratory cohort), and central nervous system (CNS) metastases (exploratory cohort).”
> “The data presented here include patients from phase 1a/1b and the measurable disease and nonmeasurable evaluable disease cohorts from phase 2.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.3-3"></a>

#### Dose escalation rules

> “Dose escalation cohorts enrolled up to 6 patients at each level; each patient was enrolled in only 1 dose cohort.”
> “In the event of 1 of 3 patients experiencing a DLT at a given dose level, a total of 6 patients would be treated at that dose level, and dose escalation would proceed if no more than 1 DLT was observed after 1 cycle of treatment. In the event of 2 or more patients experiencing DLTs at a given dose level, dose escalation stopped, and this dose level was declared the maximally administered dose.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.3-4"></a>

#### Selection of two doses for dose expansion

> “Dose selection was based on the observation of confirmed PRs at both dose levels”
> “and PK data indicating that palazestrant steady-state plasma concentrations reached the predicted efficacy threshold based on estradiol-supplemented preclinical models for both doses”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.3-5"></a>

#### Dose expansion at two dose levels (dose escalation report)

> “Phase 1b dose expansion is ongoing in the targeted dose range at 2 dose levels and will inform selection of RP2D”

Source: [Patel et al. (2021)](https://olema.com/wp-content/uploads/2023/08/Olema_Final-SABCS-Poster_11.29.21.pdf)

Additional sources: [OP-1250-001 protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/26/NCT04505826/Prot_000.pdf)

<a id="heading-3.1.2.4"></a>

### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

#### Disease and prior endocrine therapy (all phases)

> “Patients eligible for phase 1a of the study included adult men or women of any menopausal status with inoperable histologically or cytologically confirmed ER+/HER2− advanced or metastatic breast cancer who had received at least 1 prior line of endocrine therapy for advanced or metastatic disease for at least 6 months continuously and had received no more than 2 lines of prior chemotherapy regimens for metastatic disease.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.4-2"></a>

#### Exclusion of primary endocrine resistance

> “Patients who had disease progression within the first 2 years from the start of adjuvant endocrine therapy were not eligible, since these patients were considered to have tumors with primary endocrine resistance.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.4-3"></a>

#### Performance status, disease evaluability, and permitted prior therapies

> “Eligible patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and had evaluable disease. Measurable disease per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1) was not a requirement for the dose escalation phase. Prior CDK4/6 inhibitors, fulvestrant, alpelisib, everolimus, or poly-adenosine diphosphate ribose polymerase inhibitors were allowed if discontinued at least 2 weeks prior to the first dose of palazestrant.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.4-4"></a>

#### Additional criteria for phase 1b and phase 2

> “In phase 1b/2 of the study, eligible patients met the same key inclusion criteria defined in phase 1a and were also required to have measurable disease per RECIST v1.1, unless they were enrolled in the nonmeasurable disease cohort of patients with nonmeasurable but evaluable disease. In addition, patients must have received no more than 1 prior chemotherapy regimen for metastatic disease and have received at least 1 (but no more than 4) prior lines of endocrine therapy for advanced or metastatic disease.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.4-5"></a>

#### Exclusion criteria

> “Patients were excluded from all phases of the study if they had impaired cardiac function, cerebral vascular disease, or a recent thromboembolic event, an ongoing serious infection or gastrointestinal disorder that could affect absorption of study treatment, a clinically significant history of liver disease consistent with Child–Pugh class B or C, other comorbidities that could affect the patient’s ability to participate in the study, or any condition requiring medications not permitted during the study (e.g., strong CYP3 A4 inhibitors/inducers).”
> “Patients who received medications with a known risk of QT interval prolongation or Torsades de Pointes were not permitted to enroll in order to allow comprehensive assessment of QT interval prolongation in the study.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="heading-3.1.2.5"></a>

### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

#### Palazestrant regimen and dose levels

> “All patients received oral palazestrant capsules once daily, continuously in 28-day treatment cycles. In this first-in-human study, patients were required to fast for 2 h prior to and 1 h after each palazestrant dose. The initial dose cohort received a dose of palazestrant at 30 mg/day, followed by dose cohorts of 60, 90, 120, 150, 210, and 300 mg/day.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.5-2"></a>

#### Treatment duration

> “Palazestrant treatment was continued until intolerable toxicity, disease progression, study/treatment withdrawal, or death.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.5-3"></a>

#### Ovarian function suppression and restricted concomitant medications

> “Pre- or perimenopausal women were required to use luteinizing hormone–releasing hormone agonists for the duration of the study.”
> “proton pump inhibitors and most common antiemetic medications were not permitted”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.5-4"></a>

#### Selection of 120 mg/day as the recommended phase 2 dose

> “Greater clinical benefit at palazestrant 120 mg/day (46%) versus 60 mg/day (19%) led to selection of 120 mg/day as RP2D and study expansion dose.”
> “Furthermore, because patients stayed on this treatment longer, the CBR was numerically better, and the safety profile was similar to that of the 60 mg dose, this dose was further explored in phase 2 of the study.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.5-5"></a>

#### Anticipated dose range after dose escalation

> “60 mg to 120 mg was identified as the anticipated recommended phase 2 dose (RP2D) range”

Source: [Patel et al. (2021)](https://olema.com/wp-content/uploads/2023/08/Olema_Final-SABCS-Poster_11.29.21.pdf)

<a id="heading-3.1.2.6"></a>

### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

#### 3.1.2.6.1 Rationale for Using Dose-limiting Toxicity as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

##### Definition of the maximum tolerated dose and dose-limiting toxicities

> “The MTD was defined as the highest feasible dose in phase 1a in which fewer than 33% of patients (of at least 6 treated) experienced a treatment-related DLT during cycle 1. In this study, DLTs included any treatment-related fatal adverse event (AE); grade ≥ 3 nonhematologic toxicity (including nausea, vomiting, diarrhea not resolving within 3 days with optimal treatment, and fatigue lasting > 7 days); grade 3 neutropenia (with fever and/or infection); grade 3 thrombocytopenia (with bleeding); grade ≥ 4 hematologic toxicity; grade ≥ 2 AEs that resulted in treatment discontinuation or interruption for at least a week (during cycle 1) or a delay of cycle 2 for at least a week; and protocol-defined elevations of aspartate aminotransferase (AST) or alanine aminotransferase (ALT).”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.6.1-2"></a>

##### Ocular toxicity as a dose-limiting toxicity

> “Grade ≥ 3 blurred vision or retinopathy”

Source: [OP-1250-001 statistical analysis plan (2024)](https://cdn.clinicaltrials.gov/large-docs/26/NCT04505826/SAP_001.pdf)

<a id="topic-3.1.2.6.1-3"></a>

##### Safety and pharmacokinetic assessments

> “Safety assessments included the monitoring of AEs, clinical laboratory parameters, electrocardiograms, and vital signs. AE severity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 5.0).”
> “The assessment of palazestrant single- and multiple-dose PK parameters included the maximum plasma concentration (Cmax), minimum plasma concentration (Cmin), average plasma concentration (Cavg), area under the concentration–time curve from 0–24 h (AUC0–24), effective half-life (t1/2), and time to maximum plasma concentration (Tmax).”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.6.1-4"></a>

##### Efficacy end points: response, clinical benefit rate, and progression-free survival

> “Key efficacy end points included assessment of clinical response according to RECIST v1.1; the clinical benefit rate (CBR), defined as the proportion of patients who achieved a complete response (CR), achieved a partial response (PR), or had stable disease (SD) for at least 24 weeks; and progression-free survival (PFS), defined as the time from the date of the first dose to disease progression or death. Biomarker assessments included changes from baseline in circulating tumor DNA (e.g., ESR1 variants) and tumor tissue biomarkers (ERα and Ki67).”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.6.1-5"></a>

##### Electrocardiogram analysis method

> “The Corrected QT interval according to Fridericia’s formula (QTcF) and heart rate (HR) from electrocardiogram (ECG) data analysis will be conducted based on methodology recommended in the ICH E14 guideline”

Source: [OP-1250-001 statistical analysis plan (2024)](https://cdn.clinicaltrials.gov/large-docs/26/NCT04505826/SAP_001.pdf)

<a id="heading-3.1.2.7"></a>

### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

#### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

##### Planned sample size and precision

> “A sample size of approximately 30 patients per dose group in the phase 1b dose expansion cohorts was expected to provide an estimated precision of ± 19% for any binary event rate assessment. In phase 2, a sample size of approximately 50 patients treated at the RP2D was expected to provide an estimated precision of ± 15% for binary assessments.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.7.1-2"></a>

##### Participants enrolled and analyzed

> “This study enrolled 146 patients.”
> “During the dose escalation phase of the study, 42 patients were treated with once-daily oral palazestrant at doses ranging from 30 to 300 mg”
> “Baseline demographics and characteristics for all patients treated at 60 mg/day or 120 mg/day (n = 116; including those from the dose-escalation phase) are presented in Table 1.”
> “Of the 116 patients treated in the 60-mg and 120-mg dose cohorts, 92 (79.3%) patients with measurable disease were evaluable for tumor response.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.7.1-3"></a>

##### Composition of the 120 mg population

> “Includes patients from phase 1 (dose escalation and dose expansion) and phase 2 at 120 mg, and 3 patients whose dose was increased from 60 to 120 mg early in treatment.”

Source: [Lin et al. (2023)](https://ir.olema.com/static-files/d0053fca-ac05-4adc-abb4-9c6ba4ec0ae6)

Additional sources: [ClinicalTrials.gov NCT04505826](https://clinicaltrials.gov/study/NCT04505826)

<a id="heading-3.1.2.7.2"></a>

#### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

##### Analysis populations in the primary publication

> “All DLT analyses (phase 1a) were performed in patients enrolled in the study during cycle 1 and who either received 75% of the planned palazestrant doses or experienced a DLT during cycle 1. All PK analyses were performed in patients who received at least 1 dose of palazestrant and had adequate postbaseline PK samples for characterization of PK parameters. All safety analyses were performed and PFS assessed in patients who received at least 1 dose of palazestrant. Clinical response (CR or PR) was assessed in patients who received at least 1 cycle of palazestrant, had measurable disease at baseline, and had at least 1 postbaseline tumor assessment. CBR was assessed in patients who received at least 1 cycle of palazestrant, had at least 1 postbaseline tumor assessment, and started their first dose at least 24 weeks before data cutoff. Patients who discontinued study treatment without radiographic progression within 24 weeks from the first dose were not included in the CBR analysis.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.7.2-2"></a>

##### Statistical methods

> “For CBR, estimates were accompanied by 2-sided 95% confidence intervals (95% CIs). For PFS, Kaplan–Meier analyses were used to determine medians, event-free rates, and 95% CIs.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.7.2-3"></a>

##### Analysis sets in the statistical analysis plan

> “The safety analysis set (SAF) will include all subjects who received at least 1 full or partial dose of OP-1250. Subjects will be analyzed according to the OP-1250 doses they actually received as a first dose.”
> “The full analysis set (FAS) includes all subjects who received at least 1 dose of OP-1250 and have at least 1 post-baseline tumor assessment.”
> “The efficacy analysis set (EFS) will include all subjects who received at least 1 cycle of OP-1250 and have at least 1 post-baseline tumor assessment.”
> “The CBR analysis set (CBRAS) will include subjects in EFS, who started their first dose 24 weeks before data cut off. Subjects who are on treatment for less than 24 weeks, without radiographic progression per RECIST 1.1 will be excluded.”

Source: [OP-1250-001 statistical analysis plan (2024)](https://cdn.clinicaltrials.gov/large-docs/26/NCT04505826/SAP_001.pdf)

<a id="heading-3.1.2.8"></a>

### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

#### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

##### Treatment status and reasons for discontinuation at 60 or 120 mg/day

> “Among all patients treated with 60 or 120 mg/day palazestrant, 102/116 (87.9%) had discontinued treatment at the time of data cutoff (July 7, 2023) and 14 (12.1%) were ongoing. Reasons for treatment discontinuation included radiographic disease progression (n = 78 [67.2%]), clinical disease progression (i.e., without disease progression per RECIST v1.1) (n = 11 [9.5%]), AEs (n = 7 [6.0%]), withdrawal of consent (n = 4 [3.4%]), and other reasons (n = 2 [1.7%]).”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.8.1-2"></a>

##### Dose escalation disposition

> “Of 40 patients, 16 were still on treatment at the time of data cut-off, and 17 had discontinued OP-1250 due to progressive disease”

Source: [Patel et al. (2021)](https://olema.com/wp-content/uploads/2023/08/Olema_Final-SABCS-Poster_11.29.21.pdf)

Additional sources: [ClinicalTrials.gov NCT04505826](https://clinicaltrials.gov/study/NCT04505826)

<a id="heading-3.1.2.8.2"></a>

#### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

##### Baseline characteristics at 60 and 120 mg/day

| Characteristic | 60 mg (n = 30) | 120 mg (n = 86) | Total (N = 116) |
| --- | --- | --- | --- |
| Age, years; median (range) | “59.5 (30–81)” | “61.0 (32–85)” | “61.0 (30–85)” |
| Female, n (%) | “30 (100)” | “86 (100)” | “116 (100)” |
| White, n (%) | “23 (76.7)” | “70 (81.4)” | “93 (80.2)” |
| Black or African American, n (%) | “1 (3.3)” | “7 (8.1)” | “8 (6.9)” |
| Asian, n (%) | “1 (3.3)” | “3 (3.5)” | “4 (3.4)” |
| Race not reported or other, n (%) | “5 (16.7)” | “6 (7.0)” | “11 (9.5)” |
| Childbearing potential, n (%) | “0” | “7 (8.1)” | “7 (6.0)” |
| ECOG performance status 0, n (%) | “19 (63.3)” | “46 (53.5)” | “65 (56.0)” |
| ECOG performance status 1, n (%) | “11 (36.7)” | “40 (46.5)” | “51 (44.0)” |
| Measurable disease, n (%) | “29 (96.7)” | “69 (80.2)” | “98 (84.5)” |
| Visceral disease, n (%) | “24 (80.0)” | “61 (70.9)” | “85 (73.3)” |
| 1 prior line of therapy in advanced setting, n (%) | “9 (30)” | “21 (24.4)” | “30 (25.9)” |
| 2 prior lines of therapy in advanced setting, n (%) | “6 (20.0)” | “29 (33.7)” | “35 (30.2)” |
| 3 prior lines of therapy in advanced setting, n (%) | “6 (20.0)” | “19 (22.1)” | “25 (21.6)” |
| 4 prior lines of therapy in advanced setting, n (%) | “6 (20.0)” | “10 (11.6)” | “16 (13.8)” |
| 5 or more prior lines of therapy in advanced setting, n (%) | “3 (10.0)” | “7 (8.1)” | “10 (8.6)” |
| 1 prior line of endocrine therapy in advanced setting, n (%) | “12 (40.0)” | “30 (34.9)” | “42 (36.2)” |
| 2 prior lines of endocrine therapy in advanced setting, n (%) | “7 (23.3)” | “32 (37.2)” | “39 (33.6)” |
| 3 prior lines of endocrine therapy in advanced setting, n (%) | “7 (23.3)” | “15 (17.4)” | “22 (19.0)” |
| 4 prior lines of endocrine therapy in advanced setting, n (%) | “3 (10.0)” | “8 (9.3)” | “11 (9.5)” |
| 5 prior lines of endocrine therapy in advanced setting, n (%) | “1 (3.3)” | “1 (1.2)” | “2 (1.7)” |
| Prior CDK4/6 inhibitor, n (%) | “28 (93.3)” | “83 (96.5)” | “111 (95.7)” |
| Prior aromatase inhibitor, n (%) | “23 (76.7)” | “73 (84.9)” | “96 (82.8)” |
| Prior fulvestrant, n (%) | “19 (63.3)” | “57 (66.3)” | “76 (65.5)” |
| Prior chemotherapy, n (%) | “12 (40.0)” | “27 (31.4)” | “39 (33.6)” |
| ESR1 mutations (ctDNA) at baseline, n/N (%) | “15/21 (71.4)” | “36/75 (48.0)” | “51/96 (53.1)” |

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.8.2-2"></a>

##### Prior treatment at 60 and 120 mg/day

> “Patients had a median age of 61 years, the majority had measurable or visceral disease (84.5% and 73.3%, respectively), 74.1% of patients received at least 2 prior lines of systemic therapy in the advanced setting (median 2; range, 1–8), approximately two-thirds (63.8%) received at least 2 prior lines of endocrine therapy in the advanced setting (median 2; range, 1–5), and all but 5 patients (95.7%) received prior CDK4/6 inhibitor therapy.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.8.2-3"></a>

##### Prior mTOR inhibitor therapy at 120 mg

> “42% of patients received ≥3 prior lines of systemic therapy for metastatic disease”
> “mTOR inhibitor 25 (29)”

Source: [Lin et al. (2023)](https://ir.olema.com/static-files/d0053fca-ac05-4adc-abb4-9c6ba4ec0ae6)

<a id="topic-3.1.2.8.2-4"></a>

##### Dose escalation population

> “Thirty-eight patients were postmenopausal women, 1 patient was pre/perimenopausal, and 1 patient was male.”

Source: [Patel et al. (2021)](https://olema.com/wp-content/uploads/2023/08/Olema_Final-SABCS-Poster_11.29.21.pdf)

<a id="heading-3.1.2.8.3"></a>

#### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

##### Response and clinical benefit by dose level

| Endpoint | 60 mg/day | 120 mg/day |
| --- | --- | --- |
| Response-evaluable participants with measurable disease | “(n = 26)” | “66 response-evaluable patients treated with 120 mg/day palazestrant” |
| Confirmed partial responses | “2 confirmed PRs (cPRs; 7.7%)” | “3 confirmed PRs (4.5%)” |
| Unconfirmed partial responses | “1 unconfirmed PR (3.8%)” | “2 unconfirmed PRs (3.0%)” |
| All partial responses | “a total of 3 PRs (11.5%)” | “a total of 5 PRs (7.6%)” |
| Clinical benefit rate, all evaluable participants | “19.2% (95% CI, 6.6–39.4)” | “45.7% (95% CI, 33.7–58.1)” |
| Participants evaluable for clinical benefit rate | “(n = 26)” | “(n = 70)” |
| Clinical benefit rate, ESR1 mutation | “23.1% (95% CI, 5.0–53.8)” | “58.6% (95% CI, 38.9–76.5)” |
| Participants with ESR1 mutation evaluable for clinical benefit rate | “among the 13 patients with cancers with ESR1 mutations” | “(n = 29)” |

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.8.3-2"></a>

##### Confirmed response after the data cutoff and tumor shrinkage at 120 mg/day

> “One additional patient treated at the RP2D had a cPR after the data cutoff date for a total of 4 confirmed PRs (6.0%).”
> “A reduction in tumor size (percentage change less than zero) was experienced by 25/64 (39.1%) patients treated at the R2PD, including 8/64 (12.5%) who experienced a > 30% reduction”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.8.3-3"></a>

##### Duration of treatment at 120 mg/day

> “Palazestrant treatment led to prolonged disease stabilization, with 32/86 (37.2%) of patients treated at 120 mg/day remaining on treatment for ≥ 6 months and 6 (7.0%) remaining on treatment for ≥ 1 year”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.8.3-4"></a>

##### Progression-free survival at 120 mg/day, overall and with ESR1 mutation

> “The median PFS for patients receiving 120 mg/day palazestrant was 4.8 months (95% CI, 3.5–7.1), with a 6-month PFS rate of 39%”
> “In patients with cancers with ESR1 mutations treated at the R2PD, the median PFS was 5.6 months (95% CI, 4.8-NE), and the 6-month PFS rate was 47%”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.8.3-5"></a>

##### Clinical benefit rate at 120 mg by subgroup (conference presentation)

> “All patients: 40% (32/81)”
> “Prior fulvestrant: 41% (22/54)”
> “ESR1 mutation: 52% (17/33)”
> “ESR1 wild-type: 32% (12/38)”
> “3 cPRs and 2 uPRs† in 66 response-evaluable patients”

Source: [Lin et al. (2023)](https://ir.olema.com/static-files/d0053fca-ac05-4adc-abb4-9c6ba4ec0ae6)

<a id="topic-3.1.2.8.3-6"></a>

##### Second- or third-line subset at 120 mg (conference presentation)

| Population | Median PFS, months [95% CI] | 6-month PFS | CBR |
| --- | --- | --- | --- |
| All participants (n=86) | “4.6 [3.5, 6.5]” | “38%” | “40%” |
| Second or third line with or without chemotherapy (n=49) | “7.2 [3.7, 7.8]” | “54%” | “48%” |
| ESR1 mutation (n=36) | “5.6 [3.7, 7.8]” | “46%” | “52%” |
| ESR1 mutation, second or third line with or without chemotherapy (n=23) | “7.3 [5.0, NA]” | “62%” | “59%” |

Source: [Lin et al. (2023)](https://ir.olema.com/static-files/d0053fca-ac05-4adc-abb4-9c6ba4ec0ae6)

<a id="topic-3.1.2.8.3-7"></a>

##### Second- or third-line subset at 120 mg by ESR1 status (company announcement)

> “In a subset analysis of 49 patients that received palazestrant as a second- or third-line therapy with or without prior chemotherapy (the EMERALD trial eligibility criteria), the median PFS was 7.2 months and the CBR was 48% across all patients with a 6-month PFS rate of 54%. In patients with an ESR1 mutation, the median PFS was 7.3 months and CBR was 59% with a 6-month PFS rate of 62%. In ESR1 wild-type patients the median PFS was 5.5 months and the CBR was 38% with a 6-month PFS rate of 44%.”

Source: [Olema Oncology phase 2 monotherapy results announcement (2023)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-positive-phase-2-monotherapy-clinical)

<a id="topic-3.1.2.8.3-8"></a>

##### ESR1 wild-type participants at 120 mg (company announcement)

> “In ESR1 wild-type patients, the median PFS was 3.5 months and the CBR was 32% with a 6-month PFS rate of 35%.”

Source: [Olema Oncology phase 2 monotherapy results announcement (2023)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-positive-phase-2-monotherapy-clinical)

<a id="topic-3.1.2.8.3-9"></a>

##### Second- or third-line subset in the primary publication

> “In an analysis of 49 patients who received palazestrant as second- or third-line therapy with or without prior chemotherapy, the median PFS was extended to 7.2 months, with a CBR of 48% overall. Similarly, patients with cancers with ESR1 mutations had an extended PFS of 7.3 months and CBR of 59% in this subanalysis”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.8.3-10"></a>

##### Clinical benefit by on-treatment change in ESR1 mutations

> “In patients who had been treated with the RP2D of 120 mg/day palazestrant and had ctDNA available for analysis, the CBR was 73% (8/11) in patients who had a reduction in ESR1 mutations and 25% (8/32) in those who did not have a reduction in ESR1 mutations.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.8.3-11"></a>

##### Dose escalation efficacy

> “Two confirmed partial responses were achieved as of the data cut-off date, each harboring an ESR1 mutation (1 each in the 60 mg and 120 mg cohorts; Figure 3); an additional tumor response occurring in the 30 mg cohort was unconfirmed, as progressive disease occurred at a follow-up visit”
> “In the cohorts within the anticipated RP2D range, the ORR was 18% and the CBR was 38%”

Source: [Patel et al. (2021)](https://olema.com/wp-content/uploads/2023/08/Olema_Final-SABCS-Poster_11.29.21.pdf)

<a id="heading-3.1.2.8.4"></a>

#### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

#### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

##### Dose escalation: dose-limiting toxicities

> “Palazestrant doses of up to 300 mg/day resulted in no DLTs, and the MTD was not reached. The majority of treatment-emergent adverse events (TEAEs) were grade 1 or 2 in severity in all dose-escalation cohorts of palazestrant”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.8.5-2"></a>

##### Adverse events occurring in at least 15% of participants, n (%)

| Event | 60 mg any grade (n = 30) | 60 mg grade 3 | 60 mg grade 4 | 120 mg any grade (n = 86) | 120 mg grade 3 | 120 mg grade 4 |
| --- | --- | --- | --- | --- | --- | --- |
| TEAE: nausea | “14 (46.7)” | “0” | “0” | “54 (62.8)” | “3 (3.5)” | “0” |
| TEAE: vomiting | “5 (16.7)” | “0” | “0” | “25 (29.1)” | “4 (4.7)” | “0” |
| TEAE: fatigue | “13 (43.3)” | “0” | “0” | “22 (25.6)” | “3 (3.5)” | “0” |
| TEAE: neutropenia | “2 (6.7)” | “0” | “0” | “21 (24.4)” | “3 (3.5)” | “6 (7.0)” |
| TEAE: headache | “7 (23.3)” | “0” | “0” | “17 (19.8)” | “0” | “0” |
| TEAE: constipation | “6 (20.0)” | “0” | “0” | “15 (17.4)” | “0” | “0” |
| TEAE: diarrhea | “6 (20.0)” | “1 (3.3)” | “0” | “12 (14.0)” | “0” | “0” |
| TRAE: nausea | “10 (33.3)” | “0” | “0” | “47 (54.7)” | “3 (3.5)” | “0” |
| TRAE: vomiting | “3 (10.0)” | “0” | “0” | “21 (24.4)” | “2 (2.3)” | “0” |
| TRAE: fatigue | “9 (30.0)” | “0” | “0” | “17 (19.8)” | “2 (2.3)” | “0” |
| TRAE: neutropenia | “0” | “0” | “0” | “18 (20.9)” | “3 (3.5)” | “5 (5.8)” |
| TRAE: headache | “3 (10.0)” | “0” | “0” | “13 (15.1)” | “0” | “0” |

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.8.5-3"></a>

##### Treatment-emergent adverse events at 120 mg/day

> “Most patients (95.3%) who received the RP2D of 120 mg/day experienced ≥ 1 TEAE of any grade, most commonly nausea (62.8%), vomiting (29.1%), and fatigue (25.6%). The majority of TEAEs were grade 1 or 2 in severity. Grade 3 TEAEs were reported in 21 (24.4%) patients, most commonly vomiting (n = 4 [4.7%]), neutropenia, nausea, and fatigue (n = 3 each [3.5%]). Eight (9.3%) patients treated with 120 mg/day palazestrant also experienced grade 4 TEAEs, including neutropenia (n = 6), acute respiratory failure (n = 1), and 1 patient experienced 3 grade 4 events (pulmonary embolism, diverticulitis, and acute left ventricular failure).”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.8.5-4"></a>

##### Treatment-related adverse events at 120 mg/day

> “The most common TRAEs of any grade were nausea (54.7%), vomiting (24.4%), fatigue (19.8%), neutropenia (20.9%), and headache (15.1%). Grade 3 treatment-related events occurred in 10 (11.6%) patients. Nausea and neutropenia (n = 3 each [3.5%]) and vomiting and fatigue (n = 2 each [2.3%]) were the most common grade 3 TRAEs. Treatment-related grade 4 neutropenia occurred in 5 (5.8%) patients.”
> “In patients treated with the RP2D of palazestrant, the rate of treatment-related diarrhea of any grade was 13%, and there were no grade ≥ 3 events.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.8.5-5"></a>

##### Aspartate aminotransferase increase at 120 mg (conference presentation, N=83)

| Event | Grade 1 | Grade 2 | Grade 3 | Grade 4 | All, n (%) |
| --- | --- | --- | --- | --- | --- |
| AST increased | “10” | “2” | “1” | “0” | “13 (16)” |

Source: [Lin et al. (2023)](https://ir.olema.com/static-files/d0053fca-ac05-4adc-abb4-9c6ba4ec0ae6)

<a id="topic-3.1.2.8.5-6"></a>

##### Discontinuations due to adverse events and management of grade 4 neutropenia

> “Seven patients discontinued palazestrant due to AEs, of which 5 were assessed as related to palazestrant: grade 4 febrile neutropenia with no evidence of infection, grade 4 neutropenia, grade 3 nausea, grade 3 international normalized ratio increase, and grade 2 fatigue. Of the 6 patients with grade 4 neutropenia, 3 events resolved with a dose interruption (1 week) followed by a dose reduction (to 60 mg/day in 1 patient and to 90 mg/day in 2 patients); these patients continued treatment with no further neutropenia. In 3 patients, grade 4 neutropenia resolved following discontinuation of palazestrant. Grade 4 neutropenia occurred in 1 patient, concurrent with disease progression, and was assessed as not related to palazestrant.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.8.5-7"></a>

##### Timing of grade 4 neutropenia and monitoring in ongoing studies

> “While grade 4 neutropenia events occurred approximately 6-8 weeks after initiation of palazestrant, these were managed with dose interruptions or discontinuations and/or with colony-stimulating factors”
> “The mechanism underlying neutropenia is unknown, and no corresponding trends were observed in preclinical studies of palazestrant (unpublished data).”
> “All ongoing studies with palazestrant include proactive monitoring of blood counts that is more frequent during first 6–8 weeks after initiation of palazestrant, with the possibility for dose reduction or interruption following the detection of grade 3 or 4 neutropenia.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.8.5-8"></a>

##### Prior CDK4/6 inhibitor exposure among participants with grade 4 neutropenia

> “Of the 86 patients treated, events of Grade 4 neutropenia were observed in six patients, occurring approximately 4–6 weeks into therapy.”
> “All six patients had prior exposure to CDK4/6 inhibitors.”

Source: [Olema Oncology phase 2 monotherapy results announcement (2023)](https://ir.olema.com/news-releases/news-release-details/olema-oncology-announces-positive-phase-2-monotherapy-clinical)

<a id="topic-3.1.2.8.5-9"></a>

##### QTcF, bradycardia, and photopsia at 120 mg/day

> “There were no clinically significant changes in the QT interval corrected by the Fridericia formula (QTcF) in any patients treated with palazestrant, and no QTcF values exceeded 500 ms.”
> “TEAEs of oral SERDs observed in less than 10% of patients treated at the RP2D of palazestrant included bradycardia (9%) and photopsia (5%); all bradycardia and photopsia events were grade 1, and there were no dose modifications, interruptions, or discontinuations due to these events.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.8.5-10"></a>

##### Dose escalation: photopsia, bradycardia, and dose reductions

> “Two patients at 90 mg and 3 patients at 300 mg experienced photopsia (flashing lights). All events were grade 1 except for 1 event at 300 mg which was grade 2.”
> “Four patients experienced grade 1 asymptomatic bradycardia; 1 of these 4 was found to have a prior history of asymptomatic bradycardia. One patient was in the 120 mg cohort, 1 patient was in the 210 mg cohort, and 2 patients were in the 300 mg cohort. There was no interruption in OP-1250 dosing due to bradycardia.”
> “2 patients at 210 mg dose had reductions: 1 patient to 120 mg and 1 patient to 60 mg”
> “4 patients at 300 mg dose had reductions: 3 patients to 120 mg and 1 patient to 60 mg”

Source: [Patel et al. (2021)](https://olema.com/wp-content/uploads/2023/08/Olema_Final-SABCS-Poster_11.29.21.pdf)

<a id="topic-3.1.2.8.5-11"></a>

##### Grade 3 treatment-related events at 60 and 120 mg in the interim analysis

> “3 patients had a grade 3 event assessed as related to study drug: anemia (60 mg), nausea (120 mg), and fatigue (120 mg)”
> “1 patient’s dose was reduced due to a related AE of grade 1 upper abdominal pain at 120 mg”

Source: [Hamilton et al. (2022)](https://olema.com/wp-content/uploads/2022/10/Olema_ENA-2022_NCT04505826_FINAL-10.26.22.pdf)

Additional sources: [ClinicalTrials.gov NCT04505826](https://clinicaltrials.gov/study/NCT04505826)

<a id="heading-3.1.2.9"></a>

### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

#### Summary

OP-1250-001 was an open-label phase 1/2 study without a comparator arm, which the authors state limits interpretation of the safety profile and antitumor activity. Efficacy estimates come from dose cohorts of 30 participants at 60 mg/day and 86 at 120 mg/day, and only 6 participants were enrolled at 90 mg/day, during dose escalation. Response and CBR analyses used restricted populations: response required measurable disease and a postbaseline assessment (66 response-evaluable participants at 120 mg/day), and the CBR analysis excluded participants who discontinued without radiographic progression within 24 weeks. Two reports of the 120 mg cohort give different values: the peer-reviewed publication reports a CBR of 45.7% in 70 evaluable participants and a median PFS of 4.8 months, and the 2023 conference presentation reports a CBR of 40% (32/81) and a median PFS of 4.6 months. The study excluded primary endocrine resistance; fasted dosing, the exclusion of proton pump inhibitors and most common antiemetics, and a relatively large capsule may have increased gastrointestinal events. The central nervous system metastases cohort is not included in the publication, and the association between ESR1 mutation reduction and CBR is based on 11 and 32 participants (CBR 73% [8/11] versus 25% [8/32]). All 116 participants treated at 60 or 120 mg/day were women, 33.6% had received prior chemotherapy, and 8.6% had received 5 or more prior lines of therapy in the advanced setting.

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/); [Lin et al. (2023)](https://ir.olema.com/static-files/d0053fca-ac05-4adc-abb4-9c6ba4ec0ae6)

<a id="topic-3.1.2.9-2"></a>

#### Open-label design without a comparator arm

> “Limitations of this study, as with most early-phase clinical trials, include its open-label design and lack of a comparator arm that limit the interpretation of the observed safety profile and antitumor activity.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.9-3"></a>

#### Limited data at 90 mg/day

> “Limited data were available for patients treated with 90 mg palazestrant, as only 6 patients were enrolled during dose escalation.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.9-4"></a>

#### Population excluded primary endocrine resistance

> “The study did not include patients with primary endocrine resistance.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.9-5"></a>

#### Study conditions that may have increased gastrointestinal events

> “In this study, palazestrant was administered in the fasted state, proton pump inhibitors and most common antiemetic medications were not permitted, and the drug was administered in a relatively large capsule formulation, each of which could have contributed to an increased incidence of gastrointestinal events.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.9-6"></a>

#### Cross-trial comparisons and small biomarker subgroups

> “While between-study comparisons should always be made with caution because of variations in patient populations, equivalent dosing levels, and study designs”
> “While the correlation between reductions in ESR1 mutations and CBR is encouraging based on a small number of patients, these findings should be further explored in larger trials.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-3.1.2.9-7"></a>

#### Central nervous system cohort not reported

> “CNS metastases (exploratory cohort, not included in this report)”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
